Perspective: Pharmas Looking to Socialytics for Improved Market IntelligenceIDCApril 12, 2012 3 Pages - SKU: IDC3860705 |
More Social Networking reports by IDC
Vendor Assessment: Specialist Enterprise Social Software Players — Making the Financial Enterprises Social by IDC
This IDC Financial Insights report analyzes niche enterprise social software (ESS) vendors that have presence in Asia/Pacific, focusing on their Enterprise 2.0 technology tools and ...
Yotpo Private Vendor Watchlist Profile: Powering Social Reviews for Online Sellers by IDC
This IDC Vendor Profile analyzes Yotpo, a company playing in the ecommerce market, and reviews key success factors: market potential, technology/solution, corporate strategy, force multipliers, ...
Social Media Tools in Western European Vertical Markets: Maturity Levels Vary Across Sectors by IDC
This IDC study focuses on social media tools used for business purposes across vertical markets, drawing on the results of IDC's European Vertical Market Survey ...
Buyer Conversation: How Does an Online Platform Provider Leverage Social Media Marketing? by IDC
See all reports like this >>This IDC Buyer Case Study is based on a conversation IDC had with MatchMove's VP of marketing. This conversation presents some challenges the company faced ...
Research assistance
We can help you find what you need. Call us or write us: Need help in your search?
US: 800.298.5699
Int'l: +1.240.747.3093
Related Markets
- Pharmaceuticals
- Pharmaceuticals Company Reports
- Manufacturing, Packaging & Detailing
- Web 2.0
- Social Networking
Social Networking Reports
- The Digital Patient – A Snapshot of the Digital Landscape of Patients and Caregivers
- Direct to Consumer (DTC) Advertising in Pharmaceuticals - Shift from Traditional Mass-Media Platforms towards Personalization via Online and Social Media
- Pharmaceutical Digital Marketing and Social Media
- Strategies for the Effective Use of Social Media by Pharma
- The Perception of the Pharmaceutical Industry - What the Web is Saying about Health Care Reform, Safety, and Drug Costs
